Unilab, Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Unilab, Inc Pharmaceutical Import Records from India — 6 Products, $9.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unilab, Inc — Pharmaceutical Importer Profile (2026) | 6 Products, $9.6M Trade | TransData Nexus

Unilab, Inc

Pharmaceutical Importer · Philippines · Cardiovascular Focus · $9.6M Total Trade · DGFT Verified

Unilab, Inc is a pharmaceutical importer based in Philippines with a total trade value of $9.6M across 6 products in 4 therapeutic categories. Based on 200 verified import shipments from Indian Customs (DGFT) records, Unilab, Inc is the #1 buyer in 1 product including Febuxostat. Unilab, Inc sources from 7 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 45.0% of imports.

Unilab, Inc — Import Portfolio & Supplier Network

Unilab, Inc import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Unilab, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$970.4K	46	45.0%
Inventia Healthcare Limited	$534.0K	21	24.8%
Jubilant Generics Limited

What Formulations Does Unilab, Inc Import?

Formulation	Value	Ships
Pharma drug&med:valpros 500MG Each	$224.0K	8
Pharma drug&med:celabin capecita 500MG	$100.0K	2
Donepezil hcl 5MG fc tablets (dopezil)	$100.0K	2
Donepezil hcl 10MG fc tablets (dopezil)	$100.0K	2
Pharm drug&med:valpros 500MG Each film coa controlled rele tabl cont:sodium valproate BP 333MG valproic(asperinv	$69.1K	6
Pharma drug&med:renogen 10000iu/ML pfs	$60.4K	2
Pharma drugs & medicine:renogen	$60.3K	2
Pharmaceutical drugs and medicine renogen 10000iu/ML pfs (ph)	$59.3K	2
Montra 30 MG cap (isosorbide	$54.1K	2
Pharm drug&med valpros 500MG Each film coated controlled release tablet cont:sodium valproate BP 333 MG valpro(asperinv)	$53.1K	2
Ph.dru. & med.: valpros 500MG tablets (controlled release tablets of sodium valproate & valproic acid 500MG) [3x10t	$52.6K	6
Tamsulosin hcl sr pellets 0.2% batch	$50.0K	1
Pharma drugs & medicine:celabin	$50.0K	1
Donepezil hcl 5MG fc tablets (dopezil)	$50.0K	1
Donepezil hcl 10MG fc tablets (dopezil)	$50.0K	1

Unilab, Inc imports 47 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$3.4M	68	1.1%	4
2	Amlodipine	Cardiovascular	$2.3M	45	0.0%	9
3	Febuxostat	Lipid & Metabolism	$1.9M	39	4.0%	1
4	Potassium	Nutritional Supplements	$1.6M	31	0.2%	19
5	Isosorbide	Cardiovascular	$252.6K	13	0.6%	17
6	Dapagliflozin	Advanced Diabetes Medications	$200.0K	4	0.4%	19

Unilab, Inc imports 6 pharmaceutical products across 4 categories into Philippines totaling $9.6M. The company is the #1 buyer for 1 product: Febuxostat.

Unilab, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Unilab, Inc., established in 1945, is a leading pharmaceutical company headquartered in Mandaluyong City, Metro Manila, Philippines. It specializes in a comprehensive range of consumer healthcare products, including prescription and over-the-counter medications, vitamins, dietary supplements, and biotechnology products. The company operates as a subsidiary of the Unilab Group, which encompasses various entities such as UL Skin Sciences and RiteMED Phils., Inc. Unilab's extensive portfolio features well-known brands like Biogesic, Bioflu, Neozep, Solmux, Alaxan, and Enervon. (unilab.com.ph)

With a workforce exceeding 6,000 employees, Unilab is recognized as the largest manufacturer of health products in the Philippines. Its manufacturing network includes facilities like Amherst Laboratories, Inc., Amherst Parenterals, Inc., and Belmont Softgel Pharma Corporation, all adhering to stringent Good Manufacturing Practice (GMP) standards. The company's distribution capabilities ensure nationwide coverage, serving hospitals, pharmacies, drugstores, and consumers across the Philippines. (unilab.com.ph)

2Distribution Network

Unilab's distribution network is robust, encompassing multiple warehouses and logistics centers strategically located to facilitate efficient nationwide delivery. The company operates its own distribution center, First Pioneer Distribution, Inc., which enhances logistical efficiencies in distributing products across the Philippines. (unilab.com.ph) This centralized distribution system ensures timely and reliable delivery of Unilab's extensive product range to various stakeholders, including hospitals, pharmacies, and consumers.

3Industry Role

In the Philippine pharmaceutical supply chain, Unilab, Inc. functions primarily as a wholesaler and distributor. It imports, manufactures, and distributes a wide array of pharmaceutical products, serving as a key supplier to hospitals, pharmacies, and other healthcare providers. While Unilab imports certain products, it also produces a significant portion of its portfolio domestically, ensuring control over product quality and supply chain management. (unilab.com.ph)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Unilab, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Unilab's sourcing strategy from India reveals a notable concentration, with a total import value of $9.6 million USD across 200 shipments from seven unique suppliers. The top five products imported from India—Losartan, Amlodipine, Febuxostat, Potassium, and Isosorbide—account for 97.9% of the total import value. This high concentration indicates a strategic choice to maintain strong relationships with select suppliers, ensuring consistent product quality and supply reliability. The substantial import values and the number of shipments suggest stable and ongoing partnerships, reducing the risk associated with supplier dependency.

2Supply Chain Resilience

Unilab's supply chain resilience is bolstered by its diversified sourcing strategy, involving seven unique suppliers from India. The importation of 47 unique formulations across various therapeutic categories demonstrates a commitment to product diversity, mitigating risks associated with over-reliance on a single product or supplier. While the data does not specify backup suppliers, the existing supplier base and product diversity suggest a proactive approach to ensuring supply chain stability. Unilab's adherence to stringent quality standards, including compliance with local and international GMP regulations, further enhances the resilience and reliability of its supply chain. (unilab.com.ph)

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation, marketing, and distribution of pharmaceutical products. The FDA enforces regulations to ensure the safety, efficacy, and quality of drugs and health products available in the market. Key legislation governing pharmaceutical imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which provides the legal framework for the FDA's operations and responsibilities. The marketing authorization pathway for Indian generics involves obtaining FDA approval, which requires compliance with the agency's standards for product registration, labeling, and quality assurance.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that all pharmaceutical products, including those imported from India, must be registered with the FDA before they can be marketed. This process involves submitting comprehensive documentation, including product information, manufacturing details, and evidence of compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Cooperation Scheme (PIC/S). Indian exporters seeking to supply Unilab must ensure that their manufacturing facilities hold valid GMP certifications from these recognized organizations to meet regulatory requirements.

Unilab, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Unilab's focus on importing products in the cardiovascular, lipid & metabolism, and nutritional supplements categories aligns with the prevalent health concerns in the Philippines, such as hypertension, diabetes, and nutritional deficiencies. The substantial import values of key products like Losartan, Amlodipine, and Febuxostat indicate strong market demand and Unilab's strategic emphasis on these therapeutic areas. This product strategy enables Unilab to address critical health issues effectively, positioning itself as a key player in the Philippine pharmaceutical market.

2Sourcing Profile

Unilab's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, focusing on products that address prevalent health conditions in the Philippines. The company's preference for formulations over raw active pharmaceutical ingredients (APIs) allows for quicker market entry and ensures product quality through established manufacturing standards. India's well-developed pharmaceutical industry, with its adherence to international GMP standards, makes it a suitable sourcing partner for Unilab's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Unilab, Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Unilab's supply chain by offering products that complement its existing portfolio, particularly in therapeutic areas with high unmet demand. Gaps in Unilab's current sourcing may exist in specialized formulations or emerging health concerns not currently addressed. Indian exporters can explore these opportunities by ensuring compliance with FDA regulations, obtaining necessary certifications, and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters aiming to supply Unilab and the Philippine market must obtain GMP certifications from recognized international bodies such as the EU GMP, WHO GMP, or PIC/S. Additionally, they must ensure that their products are registered with the Philippine FDA, adhering to the agency's standards for product registration, labeling, and quality assurance. Maintaining compliance with these regulatory requirements is essential for successful market entry and sustained business relationships.

3How to Approach

Frequently Asked Questions — Unilab, Inc

What products does Unilab, Inc import from India?

Unilab, Inc imports 6 pharmaceutical products across 4 categories. Top imports: Losartan ($3.4M), Amlodipine ($2.3M), Febuxostat ($1.9M), Potassium ($1.6M), Isosorbide ($252.6K).

Who supplies pharmaceuticals to Unilab, Inc from India?

Unilab, Inc sources from 7 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (45.0% of imports, $970.4K).

What is Unilab, Inc's total pharmaceutical import value?

Unilab, Inc's total pharmaceutical import value from India is $9.6M, based on 200 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Unilab, Inc focus on?

Unilab, Inc imports across 4 categories. The largest: Cardiovascular (61.5%), Lipid & Metabolism (20.3%), Nutritional Supplements (16.1%).

Get Full Unilab, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.